Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Price History
|
Ratios
|
Insiders
Bullboard - Stock Discussion Forum
Coherus Oncology Inc
CHRS
Healthcare
Biotechnology
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human...
immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27. It also develops CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, Anti-ILT4 monoclonal antibody for solid tumors. In addition, the company offers GSK4381562, an antibody targeting CD112R to treat tumor cells; YUSIMRY, a biosimilar to Humira for inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, such as rheumatoid arthritis, juvenile idiop...
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Bullboard (NDAQ:CHRS)
New Post
View:
Posts & Comments
Threaded Posts
(50)
•••
Humanist
X
Post by
Humanist
on Oct 09, 2025 8:53am
CHRS: IMPT PRESENTATION UPCOMING NOV 8, 2025 12-2 PM
Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) – CHS-114, an anti-CCR8 cytolytic antibody, will also be featured in
...more
(50)
•••
Humanist
X
Post by
Humanist
on Jan 14, 2025 10:22pm
Anyone heard anything about CHRS presentation yesterday?
CHRS presented yesterday at J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 5:15 p.m. Pacific Time. The presentation and Q&A session will be accessible via Webcast through a link
...more
(50)
•••
Humanist
X
Post by
Humanist
on Dec 09, 2024 6:36pm
anyone deals with cibc experienced tech difficulties TDY?
PLS LET ME KNOW .. THX
(50)
•••
Humanist
X
Post by
Humanist
on Dec 03, 2024 9:26am
CHRS agrees to divest Udenyca for $558 mlns to INTAS
Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd. Coherus BioSciences, Inc. Tue, December 3, 2024 at 7:00 AM EST 14 min read In
...more
(50)
•••
Humanist
X
Post by
Humanist
on Nov 06, 2024 5:41pm
CHRS REPORTS 3RD QTR EARNINGS & PROVIDE BUS UPDATES TDY AMC
Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update Coherus BioSciences, Inc. Coherus BioSciences, Inc. Wed, November 6, 2024 at 4:01 PM EST 20 min read
...more
(50)
•••
Humanist
X
Post by
Humanist
on Mar 04, 2024 7:15pm
CHRS was mentioned tdy MAR. 4th by MARC CUBAN on CNBC
CHRS MENTIONED AS HAVING BIOSIMILAAR DRUGS LIKE HUMIRA THATS WAY CHEAPER ETC.. LINK BELOW FOR THE INTERVIEW ... GOOD CLIP https://www.cnbc.com/video/2024/03/04/watch-cnbcs-full
...more
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
Podcasts